Latest
Severe asthma management in pregnancy formalises around biologic continuation
Real-world evidence on biologic therapy continuation in pregnancy, structured high-risk pregnancy pulmonology integration, and updated guidelines are reshaping severe asthma in pregnancy.
Allergic bronchopulmonary aspergillosis management widens past corticosteroids and itraconazole
Biologic therapy in ABPA, novel azole maturity, and structured diagnostic-and-monitoring pathways are reshaping allergic bronchopulmonary aspergillosis management.
Severe COPD biologic therapy class emerges past the inhaler era
Dupilumab COPD approval in eosinophilic phenotype, mepolizumab and benralizumab COPD pivotal data, and ensifentrine entry are reshaping severe COPD management.
Chronic rhinosinusitis with nasal polyps biologic class matures
Dupilumab maturity, mepolizumab and benralizumab CRSwNP indications, omalizumab CRSwNP approval, and emerging mechanism programs are reshaping CRSwNP management.
By signal pillar
Clinical readouts
2IPF antifibrotic class is evolving with second-generation mechanisms
Idiopathic pulmonary fibrosis treatment has been defined by the two approved antifibrotics (pirfenidone, nintedanib) for a decade. The second-generation pipeline is now reading out, with mechanisms targeting different points in the fibrotic pathway and the potential to combine with the established class.
Severe asthma biologics: which patients are still being left out?
Type-2 biologics have transformed severe eosinophilic asthma management, but a meaningful subset of severe-asthma patients - those without high eosinophils, FeNO, or specific allergic phenotypes - still lack a biomarker-aligned biologic option.
Scientific
15Severe asthma management in pregnancy formalises around biologic continuation
Real-world evidence on biologic therapy continuation in pregnancy, structured high-risk pregnancy pulmonology integration, and updated guidelines are reshaping severe asthma in pregnancy.
Allergic bronchopulmonary aspergillosis management widens past corticosteroids and itraconazole
Biologic therapy in ABPA, novel azole maturity, and structured diagnostic-and-monitoring pathways are reshaping allergic bronchopulmonary aspergillosis management.
Severe COPD biologic therapy class emerges past the inhaler era
Dupilumab COPD approval in eosinophilic phenotype, mepolizumab and benralizumab COPD pivotal data, and ensifentrine entry are reshaping severe COPD management.
Chronic rhinosinusitis with nasal polyps biologic class matures
Dupilumab maturity, mepolizumab and benralizumab CRSwNP indications, omalizumab CRSwNP approval, and emerging mechanism programs are reshaping CRSwNP management.
Obstructive sleep apnea pharmacotherapy emerges past CPAP-and-MAD
Tirzepatide OSA approval, follow-on GLP-1 OSA programs, and upper airway pharmacological programs are reshaping obstructive sleep apnea management.
Pediatric severe asthma biologic options expand
Dupilumab, mepolizumab, benralizumab, and tezepelumab paediatric label expansions plus emerging biologic programs are restructuring paediatric severe asthma.
Refractory chronic cough acquires a first targeted mechanism class
P2X3 antagonist class entry plus follow-on novel mechanism programs are establishing chronic cough as a real prescribing category.
Sarcoidosis acquires mechanism-targeted therapy after a long quiet period
Efzofitimod late-stage data and other emerging mechanism-targeted programs are reshaping pulmonary sarcoidosis after years of corticosteroid-only first-line.
Vaping-associated lung disease as a recognised category
EVALI (e-cigarette and vaping-associated lung injury) and chronic bronchiolitis from vaping are now recognised pulmonology diagnostic categories.
PAH combination therapy moves to first-line
Pulmonary arterial hypertension upfront combination therapy is becoming standard rather than sequential single-agent escalation.
Non-CF bronchiectasis enters the therapy frontier
Late-stage programs targeting non-CF bronchiectasis are creating the first specific therapy category for this long-overlooked condition.
Infant RSV monoclonal antibody enters routine birth pathways
Long-acting RSV monoclonal antibody is becoming part of routine newborn care across high-income systems.
Adult RSV vaccination's slow-build season
Adult RSV vaccination programs are entering their second and third seasons - real-world uptake is the test.
Biologics arrive in COPD
COPD is moving from a small-molecule-only category to one with biologic options for selected phenotypes.
Severe asthma in the biologic era
Five biologic options later, the question in severe asthma is increasingly about phenotyping and switching.
Real-world evidence
2Tezepelumab uptake in type-2-low severe asthma is the field's defining commercial test
Tezepelumab's upstream mechanism (anti-TSLP) reaches patients in the type-2-low phenotype that the downstream biologic class cannot effectively serve. Real-world commercial uptake in this previously underserved population is the test of whether the upstream-mechanism advantage translates from clinical evidence to commercial reality.
COPD triple-therapy uptake remains uneven across markets
Single-inhaler triple therapy in COPD is the guideline-supported regimen for the eligible population, but real-world uptake remains uneven across major markets driven by step-therapy protocols, prescriber inertia, and access geography.